<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7446744\results\search\drug\results.xml">
  <result pre="validated by trial results. To target the inflammatory cascade, low-dose" exact="dexamethasone" post="appears to be helpful in moderate to severe cases"/>
  <result pre="(IP10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1" exact="alpha" post="(MIP1A), macrophage inflammatory protein 1 beta (MIP1B), platelet-derived growth"/>
  <result pre="1 beta (MIP1B), platelet-derived growth factor (PDGF), tumor necrosis factor" exact="alpha" post="(TNFÎ±), and vascular endothelial growth factor (VEGF) concentrations on"/>
  <result pre="on clinical outcomes in COVID-19 27 centers, Germany RCT of" exact="rivaroxaban" post="vs. SOC heparin prophylaxis Any thrombosis, all-cause mortality, or"/>
  <result pre="ACTION Trial Multiple centers, Brazil RCT of therapeutic anticoagulation with" exact="rivaroxaban" post="or enoxaparin vs. prophylactic enoxaparin Composite endpoint of mortality,"/>
  <result pre="of full dose or prophylactic dose heparin with or without" exact="clopidogrel" post="Any thrombosis at 28Â days post randomization 750 May"/>
  <result pre="Randomised Controlled Trial Charing Cross Hospital, London, UK RCT of" exact="aspirin" post="or clopidogrel or rivaroxaban with atorvastatin and omeprazole All-cause"/>
  <result pre="Trial Charing Cross Hospital, London, UK RCT of aspirin or" exact="clopidogrel" post="or rivaroxaban with atorvastatin and omeprazole All-cause mortality at"/>
  <result pre="Cross Hospital, London, UK RCT of aspirin or clopidogrel or" exact="rivaroxaban" post="with atorvastatin and omeprazole All-cause mortality at 30Â days"/>
  <result pre="London, UK RCT of aspirin or clopidogrel or rivaroxaban with" exact="atorvastatin" post="and omeprazole All-cause mortality at 30Â days after admission"/>
  <result pre="RCT of aspirin or clopidogrel or rivaroxaban with atorvastatin and" exact="omeprazole" post="All-cause mortality at 30Â days after admission 3170 March"/>
  <result pre="of COVID-19 disease. Unfortunately, the first randomized controlled trial of" exact="methylprednisolone" post="against standard of care in Beijing, China (NCT04244591) had"/>
  <result pre="conducted in the United Kingdom provided preliminary data that low-dose" exact="dexamethasone" post="reduced deaths by one-third in ventilated patients and by"/>
  <result pre="of non-steroidal anti-inflammatory drugs (NSAIDS) as therapy is extremely controversial." exact="Ibuprofen" post="is a commonly used NSAID, which is used for"/>
  <result pre="which is used for fever control, usually with acetaminophen. However," exact="ibuprofen" post="increases the synthesis of ACE2 enzyme and may potentially"/>
  <result pre="Agency (EMA) guidelines published on March 31, 2020 suggest using" exact="acetaminophen" post="for fever but also had advised not to stop"/>
  <result pre="acetaminophen for fever but also had advised not to stop" exact="ibuprofen" post="if the patient is on it for other reasons"/>
  <result pre="there are ongoing trials to assess the efficacy of inhaled" exact="ibuprofen" post="(NCT04382768) and also oral lipid formulation of ibuprofen (LIBERATE"/>
  <result pre="of inhaled ibuprofen (NCT04382768) and also oral lipid formulation of" exact="ibuprofen" post="(LIBERATE trial, Lipid ibuprofen versus standard of care for"/>
  <result pre="and also oral lipid formulation of ibuprofen (LIBERATE trial, Lipid" exact="ibuprofen" post="versus standard of care for acute hypoxemic respiratory failure"/>
  <result pre="in combination with direct-acting anti-viral agents like lopinavir, remdesivir, and" exact="ritonavir" post="to decrease the viral replication, infectivity, as well as"/>
 </snippets>
</snippetsTree>
